Curve Therapeutics has developed an innovative drug discovery platform known as the Microcycle® platform, which enables the direct screening of biologically active compounds within mammalian cells. This technology addresses the limitations of traditional drug discovery methods by allowing for the identification of small molecules that can effectively target complex disease mechanisms in their native cellular environments. The Microcycle platform facilitates the discovery of first-in-class therapeutics, particularly in oncology, by screening for compounds that can engage with challenging targets such as hypoxia-inducible factors (HIF), RAS oncogenes, and FOXA1, which are often associated with aggressive and treatment-resistant cancers.

The company is currently focused on building a robust pipeline of small molecule drugs aimed at high-priority cancer targets that have been difficult to address through conventional approaches. Their research includes dual inhibitors for HIF-1 and HIF-2, which are expected to provide significant clinical advantages in treating renal cell carcinoma and other solid tumors. Additionally, Curve is exploring inhibitors for ATIC, RAS, and FOXA1, leveraging their Microcycle platform to identify novel therapeutic candidates. This platform not only enhances the efficiency of drug discovery but also opens avenues for collaborative research and development, positioning Curve Therapeutics as a leader in addressing complex disease targets.

United Kingdom

Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged.

Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes.

We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets.

Curve Therapeutics

Company Details